Gene editing hope for immunotherapy

British scientists are developing a gene editing technique that could enable cancer cells to be destroyed by the immune system, it has been announced.

The technique involves the genetic alteration of T-cells.

It has so far been tested successfully on laboratory mice.

Scientists have removed a "switch" called PD1 from T cells. The switch sends the cells to sleep and is exploited by some kinds of cancer to avoid the immune system.

Some immunotherapy drugs tackle the same problem – but have caused severe side-effects because they act on the whole immune system.

The findings have been reported in the journal Cancer Research.

Researcher Dr Sergio Quezada, of University College London’s Cancer Institute, said: “This is an exciting discovery and means we may have a way to get around cancer’s defences while only targeting the immune cells that recognise the cancer.

“While drugs that block PD-1 do show promise, this method only knocks out PD-1 on the T cells that can find the tumour which could mean fewer side effects for patients.”

Professor Peter Johnson, chief clinician at Cancer Research UK, said: “We know that some cancers can switch off the cells of our immune system, and this interesting laboratory research suggests a new way that we might be able to get around the problem, although this is still some way away from use in the clinic."

Menger et al., TALEN-mediated inactivation of PD-1 in tumor-reactive lymphocytes promotes intratumoral T cell persistence and rejection of established tumors. Cancer Research 15 April 2016

, ,

Leave a Reply

Your email address will not be published. Required fields are marked *

Search

Categories

Monthly Posts

Our Clients

BSH
Practice Index